Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8819 |
High Similarity |
NPD3705 |
Approved |
0.8446 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.8446 |
Intermediate Similarity |
NPD4965 |
Approved |
0.8446 |
Intermediate Similarity |
NPD4966 |
Approved |
0.8433 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.8333 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.8254 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.8243 |
Intermediate Similarity |
NPD37 |
Approved |
0.8045 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7985 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7985 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7962 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7905 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7883 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7871 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7857 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7857 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7808 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7771 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7764 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7754 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7744 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7703 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7698 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7682 |
Intermediate Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.7671 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7571 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7517 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.7468 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7465 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7452 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.745 |
Intermediate Similarity |
NPD5084 |
Clinical (unspecified phase) |
0.7448 |
Intermediate Similarity |
NPD6111 |
Discontinued |
0.7445 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7436 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.7419 |
Intermediate Similarity |
NPD3384 |
Approved |
0.7419 |
Intermediate Similarity |
NPD3383 |
Approved |
0.7419 |
Intermediate Similarity |
NPD3382 |
Approved |
0.7415 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.741 |
Intermediate Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.7407 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7386 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7376 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7347 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7333 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7319 |
Intermediate Similarity |
NPD1091 |
Approved |
0.731 |
Intermediate Similarity |
NPD3657 |
Discovery |
0.7297 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7297 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7285 |
Intermediate Similarity |
NPD6783 |
Clinical (unspecified phase) |
0.7285 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7255 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7241 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7241 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7226 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7222 |
Intermediate Similarity |
NPD5109 |
Approved |
0.7222 |
Intermediate Similarity |
NPD5110 |
Phase 2 |
0.7222 |
Intermediate Similarity |
NPD5111 |
Phase 2 |
0.7214 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7212 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.72 |
Intermediate Similarity |
NPD4237 |
Approved |
0.72 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7197 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7183 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7162 |
Intermediate Similarity |
NPD4108 |
Discontinued |
0.7161 |
Intermediate Similarity |
NPD4210 |
Discontinued |
0.7153 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7152 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7152 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7152 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7152 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7152 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7143 |
Intermediate Similarity |
NPD228 |
Approved |
0.7108 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7107 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7103 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7103 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7102 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.7092 |
Intermediate Similarity |
NPD5327 |
Phase 3 |
0.7083 |
Intermediate Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.707 |
Intermediate Similarity |
NPD4675 |
Approved |
0.707 |
Intermediate Similarity |
NPD4678 |
Approved |
0.707 |
Intermediate Similarity |
NPD7028 |
Phase 2 |
0.7063 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7063 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD7157 |
Approved |
0.705 |
Intermediate Similarity |
NPD5125 |
Phase 3 |
0.705 |
Intermediate Similarity |
NPD5126 |
Approved |
0.7047 |
Intermediate Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.7047 |
Intermediate Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.7045 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7044 |
Intermediate Similarity |
NPD5563 |
Clinical (unspecified phase) |
0.7044 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7039 |
Intermediate Similarity |
NPD7466 |
Approved |
0.7039 |
Intermediate Similarity |
NPD6331 |
Phase 2 |
0.7034 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7032 |
Intermediate Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.7013 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7012 |
Intermediate Similarity |
NPD5242 |
Approved |
0.7007 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7006 |
Intermediate Similarity |
NPD7261 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD2438 |
Suspended |
0.7 |
Intermediate Similarity |
NPD5353 |
Approved |
0.7 |
Intermediate Similarity |
NPD3454 |
Phase 3 |
0.7 |
Intermediate Similarity |
NPD2161 |
Phase 2 |
0.6992 |
Remote Similarity |
NPD3022 |
Approved |
0.6992 |
Remote Similarity |
NPD3021 |
Approved |
0.6982 |
Remote Similarity |
NPD7808 |
Phase 3 |
0.698 |
Remote Similarity |
NPD6895 |
Approved |
0.698 |
Remote Similarity |
NPD6896 |
Approved |
0.6978 |
Remote Similarity |
NPD5585 |
Approved |
0.6974 |
Remote Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.6972 |
Remote Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.6964 |
Remote Similarity |
NPD6797 |
Phase 2 |
0.6963 |
Remote Similarity |
NPD7843 |
Approved |
0.6963 |
Remote Similarity |
NPD5535 |
Approved |
0.6959 |
Remote Similarity |
NPD6355 |
Discontinued |
0.6959 |
Remote Similarity |
NPD5735 |
Approved |
0.6946 |
Remote Similarity |
NPD5844 |
Phase 1 |
0.6944 |
Remote Similarity |
NPD7680 |
Approved |
0.6939 |
Remote Similarity |
NPD554 |
Clinical (unspecified phase) |
0.6939 |
Remote Similarity |
NPD1726 |
Clinical (unspecified phase) |
0.6937 |
Remote Similarity |
NPD2801 |
Approved |
0.6933 |
Remote Similarity |
NPD5588 |
Approved |
0.6929 |
Remote Similarity |
NPD17 |
Approved |
0.6928 |
Remote Similarity |
NPD6658 |
Clinical (unspecified phase) |
0.6928 |
Remote Similarity |
NPD3892 |
Phase 2 |
0.6923 |
Remote Similarity |
NPD7251 |
Discontinued |
0.6923 |
Remote Similarity |
NPD6559 |
Discontinued |
0.6914 |
Remote Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.6909 |
Remote Similarity |
NPD3926 |
Phase 2 |
0.6903 |
Remote Similarity |
NPD5297 |
Approved |
0.6892 |
Remote Similarity |
NPD2979 |
Phase 3 |
0.6892 |
Remote Similarity |
NPD2238 |
Phase 2 |
0.6889 |
Remote Similarity |
NPD5005 |
Approved |
0.6889 |
Remote Similarity |
NPD5006 |
Approved |
0.6887 |
Remote Similarity |
NPD2796 |
Approved |
0.6883 |
Remote Similarity |
NPD2219 |
Phase 1 |
0.6882 |
Remote Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.6879 |
Remote Similarity |
NPD7243 |
Clinical (unspecified phase) |
0.6871 |
Remote Similarity |
NPD919 |
Approved |
0.6867 |
Remote Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.6867 |
Remote Similarity |
NPD4538 |
Approved |
0.6867 |
Remote Similarity |
NPD6166 |
Phase 2 |
0.6867 |
Remote Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.6867 |
Remote Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.6867 |
Remote Similarity |
NPD4536 |
Approved |
0.6866 |
Remote Similarity |
NPD5451 |
Approved |
0.6863 |
Remote Similarity |
NPD5177 |
Phase 3 |
0.6863 |
Remote Similarity |
NPD3060 |
Approved |
0.6857 |
Remote Similarity |
NPD5691 |
Approved |
0.6853 |
Remote Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.6848 |
Remote Similarity |
NPD6232 |
Discontinued |
0.6842 |
Remote Similarity |
NPD5763 |
Approved |
0.6842 |
Remote Similarity |
NPD5762 |
Approved |
0.6842 |
Remote Similarity |
NPD1358 |
Approved |
0.6826 |
Remote Similarity |
NPD7473 |
Discontinued |
0.6824 |
Remote Similarity |
NPD7685 |
Pre-registration |
0.6815 |
Remote Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.6812 |
Remote Similarity |
NPD6387 |
Discontinued |
0.681 |
Remote Similarity |
NPD4055 |
Discovery |
0.6806 |
Remote Similarity |
NPD8651 |
Approved |
0.6806 |
Remote Similarity |
NPD2922 |
Phase 1 |
0.6803 |
Remote Similarity |
NPD7095 |
Approved |
0.68 |
Remote Similarity |
NPD2492 |
Phase 1 |
0.6788 |
Remote Similarity |
NPD1247 |
Approved |
0.6786 |
Remote Similarity |
NPD1182 |
Approved |
0.6784 |
Remote Similarity |
NPD7549 |
Discontinued |
0.6783 |
Remote Similarity |
NPD1840 |
Phase 2 |
0.6783 |
Remote Similarity |
NPD1608 |
Approved |
0.6782 |
Remote Similarity |
NPD6841 |
Approved |
0.6782 |
Remote Similarity |
NPD6843 |
Phase 3 |
0.6782 |
Remote Similarity |
NPD6842 |
Approved |
0.6779 |
Remote Similarity |
NPD1558 |
Phase 1 |
0.6779 |
Remote Similarity |
NPD4140 |
Approved |
0.6772 |
Remote Similarity |
NPD5976 |
Discontinued |
0.677 |
Remote Similarity |
NPD7945 |
Clinical (unspecified phase) |
0.6767 |
Remote Similarity |
NPD3134 |
Approved |
0.6765 |
Remote Similarity |
NPD1137 |
Approved |
0.6765 |
Remote Similarity |
NPD1139 |
Approved |
0.676 |
Remote Similarity |
NPD4420 |
Approved |
0.6757 |
Remote Similarity |
NPD5718 |
Phase 2 |
0.6755 |
Remote Similarity |
NPD7097 |
Phase 1 |
0.6753 |
Remote Similarity |
NPD1652 |
Phase 2 |
0.6753 |
Remote Similarity |
NPD4162 |
Approved |
0.6752 |
Remote Similarity |
NPD4123 |
Phase 3 |
0.6747 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6747 |
Remote Similarity |
NPD7229 |
Phase 3 |
0.6741 |
Remote Similarity |
NPD4750 |
Phase 3 |
0.6738 |
Remote Similarity |
NPD1651 |
Approved |
0.6736 |
Remote Similarity |
NPD3685 |
Discontinued |
0.6736 |
Remote Similarity |
NPD4359 |
Approved |
0.6733 |
Remote Similarity |
NPD230 |
Phase 1 |
0.6733 |
Remote Similarity |
NPD5124 |
Phase 1 |
0.6733 |
Remote Similarity |
NPD1933 |
Approved |
0.6733 |
Remote Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.6728 |
Remote Similarity |
NPD8455 |
Phase 2 |
0.6715 |
Remote Similarity |
NPD1138 |
Approved |
0.6713
|
Remote Similarity |
NPD422 |
Phase 1 |